GHRP-2 (pralmorelin) has a plasma half-life of approximately 15–30 minutes, based on peptide metabolism data and limited clinical pharmacokinetic studies.[1] This hexapeptide GHS-R1a agonist is cleared rapidly by proteolytic enzymes, requiring 2–3 daily subcutaneous injections to sustain pulsatile GH release. Biological GH elevation persists for 3–4 hours post-injection despite plasma clearance within 30 minutes.[3] Also known as pralmorelin or GHRP-2 acetate, this compound has been studied for GH deficiency, body composition research, and diagnostic assessment of GH axis function.
GHRP-2 has a plasma half-life of approximately 15–30 minutes. This estimate is derived from early peptide secretagogue research conducted by Bowers et al. in the late 1980s and early 1990s, which characterized the metabolic fate of synthetic hexapeptide GH secretagogues.[1] Unlike ipamorelin, which has a published formal human pharmacokinetic-pharmacodynamic study (Gobburu et al. 1999), no equivalent single-compound human PK trial for GHRP-2 has been published in the peer-reviewed literature. The half-life estimate is therefore a pharmacological inference based on the peptide's molecular characteristics and observed GH pulse dynamics in human studies.
Peptide half-lives like that of GHRP-2 are determined by measuring plasma drug concentration at serial time points after injection, then fitting the decay curve to a pharmacokinetic model. For hexapeptides of GHRP-2's size and structure, the primary clearance mechanism is proteolytic cleavage — enzymatic degradation by serum and tissue peptidases that break peptide bonds within the six-amino-acid chain. Because GHRP-2 lacks the protective modifications present in longer-acting peptides (such as PEGylation or albumin-binding motifs), it is highly susceptible to rapid degradation. Plasma protein binding is low (estimated below 20%), which means free drug is readily accessible to circulating and tissue-bound peptidases.[2]
A critical practical point is that GHRP-2's pharmacokinetic profile and pharmacodynamic effect are substantially dissociated. While plasma drug levels fall by 50% every 15–30 minutes and are effectively undetectable within 2.5 hours, the GH pulse initiated by GHRP-2's receptor activation at the pituitary is considerably more durable. Human studies by Arvat et al. (1997) and Peñalva et al. (1994) documented GH elevations persisting 3–4 hours following single subcutaneous doses.[3][4] This PK/PD offset is clinically meaningful: the effective duration of action extends well beyond what the half-life alone would predict. Researchers should account for this dissociation when designing dosing intervals and interpreting pharmacodynamic endpoints.
Using 30 minutes as the reference half-life, plasma clearance of GHRP-2 follows a predictable exponential decay. The table below shows the estimated percent of drug remaining at each successive half-life interval, with projected clearance times from a single dose. Full clearance (defined as 97% elimination) occurs at approximately 2.5 hours post-injection under this model.
GHRP-2 Plasma Clearance Timeline (Single Dose, t½ = 30 min)
| Half-Lives Elapsed | Time Post-Injection | % Remaining in Plasma | Clinical Significance |
|---|---|---|---|
| 1 | 30 min | 50% | Peak GH pulse occurring |
| 2 | 1 hr | 25% | GH pulse still elevated |
| 3 | 1.5 hr | 12.5% | GH pulse beginning to decline |
| 4 | 2 hr | 6.25% | GH returning toward baseline |
| 5 | 2.5 hr | ~3% (97% cleared) | Effectively cleared; biological effects waning |
Because GHRP-2 is cleared within approximately 2.5 hours, a single daily injection would only cover a fraction of the day with pharmacologically relevant receptor stimulation. Standard research protocols therefore target 2–3 injections per day, typically administered in the morning upon waking, post-workout or midday, and before sleep.[3] This pattern is designed to mimic the body's natural pulsatile GH secretion, which in healthy adults typically produces 5–9 pulses per 24-hour period. Pre-sleep dosing is often emphasized because endogenous GH secretion is highest during slow-wave sleep, and GHRP-2 may amplify this physiological pulse when timed appropriately. Fasting at the time of injection enhances GH response, as elevated blood glucose blunts GHS-R1a-mediated GH release.
Unlike longer-acting compounds such as CJC-1295 with DAC (half-life ~6–8 days) or MK-677 (half-life ~24 hours), a missed dose of GHRP-2 has minimal pharmacokinetic consequence beyond the loss of that individual GH pulse. Because there is no significant drug accumulation between doses, each injection is effectively a standalone event. Missing one of three daily injections reduces the total number of pharmacologically-induced GH pulses that day, but does not require dose adjustment or compensatory dosing at the next scheduled injection. This also means time-to-steady-state is not a meaningful concept for GHRP-2 — there is no accumulation phase.
The following table compares GHRP-2 to structurally related GH secretagogues across key pharmacokinetic and pharmacodynamic parameters, highlighting the importance of selectivity as a differentiating factor alongside half-life.[4]
GH Secretagogue Comparison: Half-Life & Selectivity
| Compound | Half-Life | Route | Cortisol / Prolactin Rise | GHS-R1a Selectivity |
|---|---|---|---|---|
| GHRP-2 | ~15–30 min | SC | Yes — moderate elevation | Moderate (off-target effects) |
| Hexarelin | ~30–60 min | SC | Yes — pronounced elevation | Low (strong off-target) |
| Ipamorelin | ~2 hr | SC | No significant elevation | High (selective) |
| GHRP-6 | ~15–20 min | SC | Yes — moderate elevation | Moderate; strong ghrelin-like hunger |
GHRP-2 is administered almost exclusively via subcutaneous injection in both research and clinical contexts. Oral bioavailability is negligible due to first-pass enzymatic degradation in the gastrointestinal tract; the peptide backbone is cleaved by luminal and brush-border peptidases before systemic absorption can occur. Intranasal delivery has been explored experimentally but lacks published clinical validation. For comparative context, the table below summarizes available data across administration routes.
Pharmacokinetics by Route
| Route | Bioavailability | Half-Life | Tmax | Notes |
|---|---|---|---|---|
| Subcutaneous (SC) | High (estimated) | ~15–30 min | ~15–30 min | Standard research route; well-characterized GH response |
| Intravenous (IV) | 100% (by definition) | No published dosing data | Immediate | Used in diagnostic GH stimulation tests; not standard for protocols |
| Oral | Negligible (<1%) | N/A | N/A | Degraded by GI peptidases; not a viable route |
| Intranasal | Low (not established) | Not established | Not established | Transmucosal delivery explored but not validated in published literature |
GHRP-2 is not included in standard clinical urine drug screens (e.g., SAMHSA-5 or expanded workplace panels) or routine immunoassay-based testing. These panels target specific drug classes — opioids, stimulants, benzodiazepines, cannabinoids, and similar pharmaceuticals — and GHRP-2 does not cross-react with any standard immunoassay target. A researcher or patient taking GHRP-2 would not generate a positive result on any standard drug test currently in clinical use.
Peptide detection in anti-doping or specialized forensic contexts requires liquid chromatography tandem mass spectrometry (LC-MS/MS) or similar high-resolution methods capable of identifying intact peptide sequences or specific fragmentation patterns. The World Anti-Doping Agency (WADA) has developed methods for detecting growth hormone secretagogues including GHRP-2 in urine and blood samples. Given the plasma half-life of approximately 30 minutes and full clearance within 2.5 hours, the practical detection window for GHRP-2 in plasma is similarly narrow — estimated at a few hours post-injection under optimal conditions. No peer-reviewed study has formally characterized the forensic detection window in human subjects.
GHRP-2 is a synthetic hexapeptide — a chain of six amino acids (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) — developed by Cyril Bowers and colleagues in the early 1980s as a synthetic mimic of the endogenous GH-releasing activity observed with certain enkephalin analogs.[2] The short half-life is a direct consequence of the peptide's chemical structure: unmodified linear peptides are highly vulnerable to circulating serum peptidases, including dipeptidyl peptidase IV (DPP-IV), neprilysin, and other endopeptidases distributed throughout plasma and vascular endothelium. These enzymes cleave the GHRP-2 backbone at susceptible peptide bonds, rapidly inactivating the compound. The incorporation of D-amino acids at two positions (D-Trp and D-Phe) provides partial resistance to exopeptidase degradation, but the overall half-life remains extremely short compared to modified peptides or small-molecule mimetics like MK-677.
GHRP-2 exerts its primary pharmacological effect via agonism at the GHS-R1a receptor (growth hormone secretagogue receptor type 1a), which is the same receptor targeted by the endogenous hormone ghrelin and by related synthetic secretagogues such as ipamorelin, hexarelin, and MK-677. GHS-R1a is expressed predominantly on somatotroph cells in the anterior pituitary and on specific hypothalamic neurons involved in GH regulation. When GHRP-2 binds GHS-R1a, it triggers a Gq/11-protein signaling cascade that mobilizes intracellular calcium, stimulating the pulse release of stored growth hormone from pituitary somatotrophs.[1]
Unlike ipamorelin, which binds GHS-R1a with high selectivity, GHRP-2 also interacts with secondary receptors or hypothalamic signaling pathways — the precise mechanism is incompletely characterized but likely involves corticotropin-releasing hormone (CRH) neurons and dopaminergic circuits — resulting in co-secretion of ACTH (and downstream cortisol) and prolactin alongside GH.[4] This non-selectivity is a defining pharmacological feature of GHRP-2 that distinguishes it from newer-generation secretagogues. For research purposes, reported GH responses to GHRP-2 must be interpreted in the context of this concurrent cortisol and prolactin activation, which selective secretagogues do not produce. The cortisol co-release is generally considered modest and transient, but may be a relevant consideration in protocols where sustained cortisol elevation is undesirable.
Log doses, visualize GH pulse timing, and track biomarkers — all in the Halflife app. Built for researchers and protocol-focused users.
Download Halflife — FreeExplore half-life and pharmacokinetic data for related GH axis compounds:
Log injections, visualize GH pulse timing across your 2–3× daily protocol, and monitor cortisol, IGF-1, and other biomarkers over time. Halflife is the dedicated app for peptide and GLP-1 protocol tracking.
Download on the App Store